Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Committee backs biomarker‑coverage bill after insurers urge narrower language
Summary
The committee passed HB1121 to expand coverage for biomarker testing to guide cancer treatment; sponsors and clinical advocates called it potentially life‑saving, while Arkansas Blue Cross warned language could force payment for investigational screening tests and estimated major cost impacts.
The Insurance & Commerce Committee voted to advance HB1121, a bill intended to require coverage for biomarker testing in cancer management, after sponsors said the legislation will save lives and provide clinicians tools for precision treatment.
Senator Dave Wallace and Representative Fred Allen, the bill’s sponsors, said the measure focuses on biomarkers used to guide treatment decisions rather than population screening or initial diagnosis. Wallace…
Already have an account? Log in
Subscribe to keep reading
Unlock the rest of this article — and every article on Citizen Portal.
- Unlimited articles
- AI-powered breakdowns of topics, speakers, decisions, and budgets
- Instant alerts when your location has a new meeting
- Follow topics and more locations
- 1,000 AI Insights / month, plus AI Chat
